Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
45
25
26
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 45 trials
100.0%
+13.5% vs industry average
40%
18 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (45)
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants
Role: lead
A Study of HDM2024 in Participants With Advanced Solid Tumors
Role: lead
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Role: lead
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
Role: lead
Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
Role: collaborator
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
Role: lead
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Role: lead
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Role: lead
A Study of HDM2006 in Patients With Advanced Solid Tumor
Role: lead
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
Role: lead
Single-Arm Clinical Study of Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Patients at High Risk of Postoperative Recurrence
Role: collaborator
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
Role: lead
Phase Ib Clinical Study of HDM1005 Injection
Role: lead
Phase Ia Clinical Study of HDM1005 Injection
Role: lead
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Role: lead
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
Role: lead
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Role: lead
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Role: lead
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
Role: lead
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Role: lead